Merrill Wise, MD
Sleep Medicine · Memphis, TNNPI 1922089192
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 36.5% of the total. Reporting peaked in 2019 at $2,646 and has fallen 77.0% since, to $610 in 2025.
Across 216 payments — averaging $34.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$3K
- Harmony Biosciences LLC$1K
- United Therapeutics Corporation$557
- AstraZeneca$520
- ZOLL Medical Corporation$480
- Boehringer Ingelheim$394
- plus $2K from 22 others
What the payments were for
- Consulting fees$2,94040%
- Food & beverage$4,18056%
- Education$3104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 9 | $2,712 |
| Harmony Biosciences LLC | 39 | $1,178 |
| United Therapeutics Corporation | 28 | $557 |
| AstraZeneca(2 entities) | 26 | $520 |
| ZOLL Medical Corporation | 1 | $480 |
| Boehringer Ingelheim | 27 | $394 |
| Sanofi | 20 | $337 |
| La Jolla Pharmaceutical Company | 9 | $207 |
| Philips North America LLC | 7 | $163 |
| Merck | 8 | $131 |
| Grifols USA, LLC | 8 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $63 |
| Fisher & Paykel Healthcare Inc | 2 | $52 |
| Genentech USA, Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $49 |
| Bayer | 3 | $46 |
| Baxter Healthcare | 2 | $44 |
| ZOLL Respicardia, Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 1 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $38 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $29 |
| Gilead | 2 | $25 |
| Pulmonx Corporation | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Vapotherm Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUNOSI$2,460
How this compares
$7,431 in reported general payments places this provider in the 85th percentile of 41 sleep medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 13 | $260,725 |
| WakixPitolisant Hcl | 11 | $170,810 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,817 |
| Armodafinil | 44 | $4,477 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 71 | $3,797 |
| Modafinil | 29 | $2,083 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $621 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 24 | $329 |
| Trazodone Hcl | 33 | $300 |
| Clonazepam | 54 | $255 |
| Gabapentin | 32 | $199 |
| Zolpidem Tartrate | 16 | $85 |
| Zaleplon | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $1,178 | $170,81011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $71 | $4,81713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 sleep medicine providers in Tennessee.
Other sleep medicine in Memphis
- James AndrewsMemphis$4K
- William MariencheckMemphis$3K
- Syed ZaidiMemphis$1K
- Ariel LongMemphis$828
- John McGeheeMemphis$17
- Bijoy JohnBrentwood$38K
- Kelly CardenNashville$24K
- Martha HagamanFranklin$20K
- John DenglerJohnson City$19K
- Prashant JamesKnoxville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.